Chris Scotto DiVetta, SVP and General Manager, AI Applications at Tempus Labs, shared a post on LinkedIn:
“If you’re in the lab industry, you’ve heard about the failure mode, QNS or ‘Quantity-Not-Sufficient’. This is when there is not enough specimen to deliver a test result.
Now, cancer tissue is scarce, and as precision medicine permeates care pathways, the demands on it are exponentially increasing.
At Tempus AI, we feel a deep responsibility to serve as stewards of this precious resource. That’s why we are working on an AI system that analyzes digitized images of HandE-stained pathology slides to predict nucleic acid yield on samples that come through our lab to determine if the sample is likely to QNS. Providers can then decide on alternative approaches that might better inform next steps for the patient. Read the details from Nike Beaubier and Jason Blue-Smith below.
We also continue to invest in using HandEs to pre-screen for relevant biomarkers, including with our acquisition of the market leader in this research, Paige.
Our goal is to continue to make precision medicine accessible to all patients, even if the ‘Quantity(is)-Not-Sufficient.’ ”
More posts featuring Chris Scotto DiVetta.